All Professionals
Overview
Samantha Eldredge is a partner in the Corporate Department of Paul Hastings and is based in the firm’s Palo Alto office.
Samantha’s practice focuses on securities and capital markets and mergers and acquisitions. She represents public and private companies, investors and agents in a wide range of corporate matters, including mergers and acquisitions, private equity financings, strategic transactions, securities offerings, corporate governance and compliance, periodic reporting requirements and other general corporate matters.
Samantha’s work for clients, such as Viking Therapeutics in its initial public offering and follow-on public offering, has been mentioned in Dealmakers, The Daily Journal and Law360.
Samantha received a B.A. degree with high honors in Rhetoric and Chinese Language and Literature from the University of California at Berkeley in 2004. She received a J.D. degree from Santa Clara University School of Law, cum laude, in 2007, where she was a Dean’s Fellowship Scholar.
Accolades
- Capital Markets: Equity Offerings, Legal 500 USA
- Northern California Rising Stars List, Super Lawyers
Education
- Santa Clara University School of Law, J.D. (cum laude) 2007
- University of California at Berkeley, B.A. 2004
Representations
- Xencor in its underwritten public offering.
- Kyverna Therapeutics in its initial public offering.
- Jasper Therapeutics in its reverse merger (deSPAC) and financing transactions.
- Corcept Therapeutics in its self-tender offer.
- Scilex Holding Company in its reverse merger (deSPAC) with Vickers Vantage Corp. I.
- Mohawk Group Holdings in its initial public offering.
- Onestream Software in its financing by KKR.
- Scilex Pharmaceuticals in its debt financing structured by Morgan Stanley.
- Seelos Therapeutics in its reverse merger with Apricus Biosciences.
- Plum in its preferred stock financing by Elliot Management.
- Redmile Group in its preferred stock financing of Alder BioPharmaceuticals.
- Menlo Technologies in its acquisition of SSi Consulting.
- Corsair Components in its sale to EagleTree Capital.
- Mission Bio in its preferred stock financing transactions.
- TNK Therapeutics in its acquisition of Virttu Biologics.
- Sorrento Therapeutics in its follow-on public offering and financing transactions.
- CareDx in its debt financing by JGB Management.
- J.T. Posey Company in its sale to RoundTable Healthcare Partners.
- Matrix Industries in its equity and debt financing transactions.
- Eprazel in its strategic financing by Renren.
- Sorrento Therapeutics in its acquisition of Scilex Pharmaceuticals.
- CareDx in its underwritten public offerings.
- Veriflow Systems in its financing by Menlo Adventures and New Enterprise Associates (NEA).
- Filld in its financings by Lightspeed Partners, Javelin Partners and PivotNorth
- Boomtown Networks in its strategic financings.
- Viking Therapeutics in its initial public offering, follow-on public offerings and equity line financings.
- Samsung Fine Chemicals and Samsung Electronics in their respective investments in SunEdison Semiconductor’s initial public offering through concurrent private placement transactions.
- Integrated DNA Technologies in the strategic financing by Summit Partners.
- Samsung Electronics in the sale of its joint venture stake to, and strategic investment in, Corning Incorporated.
- BioMarin Pharmaceutical in connection with its follow-on public offerings of common stock.
- Fox Factory Holding in its initial public offering.
- Corsair Components in the strategic financing by Francisco Partners.
- Procera Networks in its acquisition of Vineyard Networks.
- The underwriters, led by Goldman Sachs and Deutsche Bank Securities, in the initial public offering of Envivio.
- Monitise in connection with its acquisition of ClairMail.
- The underwriters, led by Stifel Nicolaus Weisel, in the public offering of Procera Networks.
- The underwriters, led by Stifel Nicolaus Weisel and Needham & Company, in the public offering of OCZ Technology Group.
- Masimo Corporation in its acquisitions of Phasein AB and Spire Semiconductor.
- Warburg Pincus in its exchangeable bond investment in Synutra International.
- Houlihan Lokey as the placement agent in the registered direct offering of ThermoGenesis.
- Hanwha Chemical in its strategic investment in Solarfun Power Holdings (now Hanwha SolarOne).
- Mint Software in its sale to Intuit.
News
- Paul Hastings Advises Stifel and Needham on VIAVI’s $557.2 Million Common Stock Offering - May 21st, 2026
- Paul Hastings Advises Organovo Holdings in Sale of FXR Program to Eli Lilly - March 26th, 2025
- Paul Hastings Advising Aardvark Therapeutics on Its IPO - February 13th, 2025
- Paul Hastings Advised Xencor, Inc. on $175 Million Common Stock Underwritten Public Offering - September 13th, 2024
- Paul Hastings Advised Viking Therapeutics on its $632.5 Million Public Offering of Common Stock - March 4th, 2024
- Paul Hastings Advised Kyverna Therapeutics on $319 Million Upsized IPO - February 9th, 2024
- Paul Hastings Advised Jasper Therapeutics on $50 Million Common Stock Offering - February 8th, 2024
- Paul Hastings Advised Corcept Therapeutics in its $145.4 Million Tender Offer - April 7th, 2023
- Paul Hastings Advised Viking Therapeutics in its $287.5 Million Public Offering of Common Stock - April 6th, 2023
- Paul Hastings Advised Jasper Therapeutics in $103.5 Million Public Offering - January 27th, 2023